靶向CLDN18.2在胃癌治疗中的研究进展
Advances of targeting CLDN18.2 in the treatment of gastric cancer
牛幸栋 1王军宏 2张文燕 1达明绪3
作者信息
- 1. 730030 兰州 甘肃中医药大学第一临床医学院
- 2. 730900 白银市第一人民医院肝胆外科;730099 兰州大学第一临床学院
- 3. 730099 甘肃省人民医院肿瘤外科
- 折叠
摘要
Claudin18.2(CLDN18.2)属于Claudin蛋白家族的一员,是CLDNs18 的亚型之一.CLDNs18 是一种具有高度组织特异性的蛋白,在细胞的紧密连接中发挥着重要的作用,并且参与肿瘤细胞的增殖、分化和迁移.最近的研究表明,Clau-din18.2 高度选择、稳定地表达于胃癌,因此被认为是目前胃癌靶向治疗最具潜力的靶点.目前靶向CLDN18.2 的抗肿瘤治疗已经从单一的单克隆抗体发展至具有不同免疫调节机制的双特异性抗体,包括嵌合抗原受体T(CAR-T)细胞疗法、抗体药物偶联物(ADC)等.本文就CLDN18.2 在胃癌中的表达水平和临床意义,以及目前针对CLDN18.2 的治疗现状作一简单综述.
Abstract
Claudin18.2(CLDN18.2),a member of the Claudin protein family,is one of the subtypes of CLDNs18.It is a highly tissue-specific protein that plays an important role in cellular tight junctions and is also involved in the proliferation,differentiation and migration of tumor cells.Recent studies have shown that Claudin18.2 is highly selective and stably expressed in gastric cancer and is therefore considered to be the most promising target for targeted gastric cancer therapy.Currently,antitumor therapy targeting CLDN18.2 has developed from single monoclonal antibody to bispecific antibody,including chimeric antigen receptor T cell therapy,and antibody drug conjugate with different regulatory mechanisms.In this article,the expression level of CLDN18.2 in gastric cancer,its clinical significance and its present therapeutic condition were briefly reviewed.
关键词
胃癌/Claudin18.2/嵌合抗原受体T细胞/抗体药物偶联物/综述Key words
Gastric cancer/Claudin18.2/Chimeric antigen receptor T cells/Antibody-drug conjugates/Overview引用本文复制引用
出版年
2024
NETL
NSTL
万方数据